Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity

Garrett, J E; Lanes, S F; Kolbe, J; Rea, H H
November 1996
Thorax;Nov1996, Vol. 51 Issue 11, p1093
Academic Journal
No abstract available.


Related Articles

  • The 'Crashing Asthmatic'. HIGGINS, JAMES C. // American Family Physician;2015 Special Issue, Vol. 91, p1 

    Asthma is a common chronic disorder, with a prevalence of 8 to 10 percent in the U.S. population. From 5 to 10 percent of patients have severe disease that does not respond to typical therapeutic interventions. To prevent life-threatening sequelae, it is important to identify patients with...

  • Long-acting β-adrenoceptor agonists increase asthma risks.  // Reactions Weekly;7/1/2006, Issue 1108, p3 

    The article focuses on a study that investigated the risk of severe asthma attacks that lead to hospitalizations and death associated with the use of long-acting β-adrenoreceptor agonists. Those who received the adrenoreceptor agonists showed increased odds ratios for asthma-related...

  • LABAs: not to be used alone.  // Monthly Prescribing Reference;Mar2010, Vol. 26 Issue 3, pA18 

    The article reports that the use of long-acting beta agonists (LABAs) are associated with an increased risk of severe worsening of asthma symptoms and may cause hospitalization and death, thus, they should never be used alone to treat asthma.

  • Long-acting beta-agonists: More dangerous than we thought? Aschgoodkin, Judith; Kaplan, Deborah // Patient Care;Aug2006, Vol. 40 Issue 8, p13 

    The article discusses research on the role of long-acting beta-agonists (LABA) in the management of asthma. According to research, LABAs may increase severe and life-threatening asthma exacerbations, hospitalizations, intensive care unit admissions, and asthma-related deaths. The factors that...

  • What Are the Risks of Using Inhaled Long-Acting Beta-Agonist Medications for the Relief of Asthma? Salpeter, S. R.; Buckley, N. S.; Ormiston, T. M.; Salpeter, E. E. // Annals of Internal Medicine;6/20/2006, Vol. 144 Issue 12, pI30 

    The article explains the risks of using inhaled long-acting beta-agonist medications for the relief of asthma. Asthma is a disease that is usually caused by inflammation of the bronchial tubes. Symptomatic treatment of asthma with long-acting beta-agonist medications carries with it some...

  • Circumstances of death from asthma. Johnson, A.J.; Nunn, A.J.; Somner, A.R.; Stableforth, D.E.; Stewart, C.J. // British Medical Journal (Clinical Research Edition);6/23/1984, Vol. 288 Issue 6434, p1870 

    Reports several deaths due to asthma in Great Britain. Development of Beta agonist bronchodilators and corticosteroid in treating asthma; Sets of circumstances in the fatal attack of asthma; Suggestion to patients to monitor the severity of asthma.

  • Citations and Clinicians' Notes: Asthma.  // Current Medical Literature: Respiratory Medicine;2003, Vol. 17 Issue 4, p96 

    Presents several abstracts on citations and clinicians' notes regarding asthma in Great Britain. "Systematic assessment of difficult-to-treat asthma," by Robinson D.S., Campbell D.A., Durham S.R., Pfeffer J., Barnes P.J., and Chung K.F.; "Bronchoalveolar lavage cytokine profiles in acute asthma...

  • Asthma patient hospitalization risk more than doubles with long-acting beta-agonist use of 3 months.  // Formulary;Jul2006, Vol. 41 Issue 7, p312 

    The article discusses the finding from a meta-analysis of 19 randomized clinical studies which suggests that long-acting beta-agonists (LABAs) more than double the rates at which asthma patients may be hospitalized. According to the study's authors, removal of LABA from the market would make its...

  • Weighing up risks in the use of LABAs. Upadhyay, Neil // GP: General Practitioner;2/16/2007, p35 

    The article assesses the risks involved in the use of long-acting beta-2 agonists (LABAs). LABAs should be used after a trial of low-dose inhaled corticosteroids and before the dose of inhaled corticosteroids is increased. LABAs are used to treat patients whose asthma is so severe that treatment...

  • Review: long acting β agonists increase severe asthma exacerbations and asthma related deaths in children and adults. Salpeter, S. R.; Buckley, N. S.; Ormiston, T. M. // Evidence Based Medicine;Feb2007, Vol. 12 Issue 1, p10 

    The article presents a study regarding the use of long acting beta agonists in patients with asthma. In assessing the study, a randomized controlled trials that compared salmeterol, formoterol or eformoterol with placebo are employed. The results suggest that long acting beta agonists increase...


Read the Article


Sign out of this library

Other Topics